Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?

Journal of the American College of Surgeons

Volumn 206, Issue 5, 2008, Pages 879-886

  McLoughlin, James M ^a   Melis, Marcovalerio ^b   Siegel, Erin M ^b   Dean, E Michelle ^c   Weber, Jill M ^b   Chern, Jeannie ^b   Elliott, Melanie ^b   Kelley, Scott T ^b   Karl, Richard C ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; DATA BASE; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY; REMISSION INDUCTION;

EID: 42949095186     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.12.027     Document Type: Article

References (65)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Surveillance Epidemiology and End Results (SEER) (2007), National Cancer Institute
3. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
4. Crew K.D., and Neugut A.I. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31 (2004) 450-464
5. Devesa S.S., and Fraumeni Jr. J.F. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 91 (1999) 747-749
6. Wu A.H., Wan P., and Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12 (2001) 721-732
7. Headrick J.R., Nichols III F.C., Miller D.L., et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 73 (2002) 1697-1702 discussion 1702-1693
8. Ellis Jr. F.H., Heatley G.J., Krasna M.J., et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 113 (1997) 836-846 discussion 846-838
9. Killinger Jr. W.A., Rice T.W., Adelstein D.J., et al. Stage II esophageal carcinoma: the significance of T and N. J Thorac Cardiovasc Surg 111 (1996) 935-940
10. Lerut T.E., de Leyn P., Coosemans W., et al. Advanced esophageal carcinoma. World J Surg 18 (1994) 379-387
11. Lieberman M.D., Shriver C.D., Bleckner S., and Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 109 (1995) 130-138 discussion 139
12. Millikan K.W., Silverstein J., Hart V., et al. A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. Arch Surg 130 (1995) 617-624
13. Sabanathan S., Shah R., Mearns A.J., et al. Results of surgical treatment of oesophageal cancer. J R Coll Surg Edinb 41 (1996) 295-301
14. NCCN Clinical Practice Guidelines in Oncology. www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf Accessed November 2007
15. th ed. (2002), Lippincott Raven Publishers, Philadelphia, PA
16. Coia L.R., Engstrom P.F., Paul A.R., et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20 (1991) 29-36
17. Valerdi J.J., Tejedor M., Illarramendi J.J., et al. Neoadjuvant chemotherapy and radiotherapy in locally advanced esophagus carcinoma: long-term results. Int J Radiat Oncol Biol Phys 27 (1993) 843-847
18. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
19. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
20. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
21. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
22. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
23. Urba S.G., Orringer M.B., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
24. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
25. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
26. Siewert J.R., Stein H.J., Feith M., et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234 (2001) 360-367 discussion 368-369
27. Collard J.M., Otte J.B., Fiasse R., et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 234 (2001) 25-32
28. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73 (1994) 2680-2686
29. Bedenne L., Seitz J.F., Milan C., et al. [Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study]. Gastroenterol Clin Biol 22 (1998) 273-281
30. Keller S.M., Ryan L.M., Coia L.R., et al. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer 83 (1998) 1908-1916
31. Meluch A.A., Hainsworth J.D., Gray J.R., et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 5 (1999) 84-91
32. Posner M.C., Gooding W.E., Landreneau R.J., et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am 4 (1998) 237-246
33. Raoul J.L., Le Prise E., Meunier B., et al. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys 42 (1998) 29-34
34. Tamim W.Z., Davidson R.S., Quinlan R.M., O'Shea M.A., Orr R.K., and Swanson R.S. Neoadjuvant chemoradiotherapy for esophageal cancer: is it worthwhile?. Arch Surg 133 (1998) 722-726
35. Wright C.D., Wain J.C., Lynch T.J., et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 114 (1997) 811-815 discussion 816
36. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
37. Makary M.A., Kiernan P.D., Sheridan M.J., et al. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy. Am Surg 69 (2003) 693-700 discussion 700-692
38. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
39. Stahl M., Wilke H., Stuschke M., et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 131 (2005) 67-72
40. Bedenne L.M.P., Bouche O., et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 21 (2002) 519
41. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78 (2004) 1152-1160 discussion 1152-1160
42. Jones D.R., Parker Jr. L.A., Detterbeck F.C., and Egan T.M. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85 (1999) 1026-1032
43. Beseth B.D., Bedford R., Isacoff W.H., Holmes E.C., and Cameron R.B. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 66 (2000) 827-831
44. Erasmus J.J., Munden R.F., Truong M.T., et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1 (2006) 478-486
45. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 (2007) 1385-1391
46. Levine E.A., Farmer M.R., Clark P., et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243 (2006) 472-478
47. Mamede M., Abreu E.L.P., Oliva M.R., et al. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 30 (2007) 377-388
48. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
49. Port J.L., Lee P.C., Korst R.J., et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 84 (2007) 393-400 discussion 400
50. Song S.Y., Kim J.H., Ryu J.S., et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1053-1059
51. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
52. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
53. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21 (2003) 428-432
54. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
55. Hautzel H., and Muller-Gartner H.W. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38 (1997) 1384-1386
56. Greven K.M., Williams III D.W., McGuirt Sr. W.F., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23 (2001) 942-946
57. Lowe V.J., Boyd J.H., Dunphy F.R., et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 18 (2000) 651-658
58. Herder G.J., Golding R.P., Hoekstra O.S., et al. The performance of (18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 31 (2004) 1231-1236
59. Lindell R.M., Hartman T.E., Swensen S.J., et al. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. AJR Am J Roentgenol 185 (2005) 126-131
60. Lowe V.J., Fletcher J.W., Gobar L., et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16 (1998) 1075-1084
61. Nakamura R., Obara T., Katsuragawa S., et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 20 (2002) 181-186
62. Weber W.A., and Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 31 (2004) 530-541
63. Lowe V.J., Booya F., Fletcher J.G., et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 7 (2005) 422-430
64. Meyers B.F., Downey R.J., Decker P.A., et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133 (2007) 738-745
65. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 (2007) 797-805